PTK2 and cancer: Hence, despite the fact that blocking Fak function may represent a therapeutic opportunity in some cancers (Ashton et al, 2010; Lee et al, 2015), our findings are more aligned with a previous study (Macagno et al, 2014) that suggested that, at least in the context of Ret‐driven tumorigenesis, Fak can act as a tumour suppressor.